Sernova Corp.

63 articles with Sernova Corp.

• 

  BioSpace Movers & Shakers, Oct. 25

  10/25/2019

  Pharma and life sciences companies strengthen their executive and leadership teams with this week's appointments.

• Sernova Confirms Enduring Levels of Fasting C-Peptide in Bloodstream of First Patient in its Phase I/II Clinical Trial for Type-1 Diabetes

  10/16/2019

  Findings further validate Cell Pouch and therapeutic cell performance in

• 

  BioSpace Global Roundup, Aug. 22

  8/22/2019

  Companies from across the globe provide updates on their business and pipelines.

• Sernova Announces First Closing of Private Placement

  8/19/2019

  Sernova Corp., a clinical-stage regenerative medicine company, is pleased to announce that it has completed a first closing of $2,333,500 of its non-brokered private placement, of which $64,000 was closed under the “Existing Shareholder Exemption.”

• Sernova's Phase I/II US Clinical Trial for Type-1 Diabetes Advances Following Positive Preliminary Safety and Efficacy Data

  7/18/2019

  Sernova Corp. (TSXV:SVA) (FSE:PSH) (OTCQB:SEOVF), a clinical-stage regenerative medicine company today announced that its human Phase I/II clinical trial for type-1 diabetes is advancing with additional patients for device and cell transplantation.

• 

  BioSpace Global Roundup, July 18

  7/18/2019

  Pharma and biotech companies from across the globe provide updates on their pipelines and corporate strategy.
• 

  BioSpace Global Roundup, July 11

  7/11/2019

  Companies from across Europe, Asia and around the globe share pipeline and business updates.

• Sernova Corp Presents Positive Preliminary Safety and Efficacy Data in its Phase I/II Clinical Trial for Type-1 Diabetes

  7/3/2019

  Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF), a clinical-stage regenerative medicine company today announced that in an interim analysis of its human Phase I/II clinical trial, Sernova's Cell Pouch transplanted with islet cells showed initial safety, as well as key efficacy measures, including glucose-stimulated C-peptide, insulin production and additional clinically significant measures of glucose control in the first study patient with type-1 diabetes and severe hypoglycemia unawareness. 

• Sernova Announces $2,000,000 First Closing of Private Placement

  7/16/2018

  Due to Oversubscription, Offering Increased to $2,700,000

• Sernova Initiates Patient Screening and Recruitment for its US Clinical Trial for Diabetes

  7/5/2018

  Sernova Corp. announces that patient screening and recruitment has begun in its regenerative medicine US clinical trial for diabetic patients with hypoglycemia unawareness.

• Sernova Receives U.S. FDA IND Allowance to Initiate a U.S. Clinical Trial of its Cell Pouch for the Treatment of Type 1 Diabetes

  12/11/2017

  Sernova plans to initiate the new clinical trial under this US IND to investigate the Cell Pouch for tT1D in individuals with hypoglycemia unawareness.

• Sernova Corp. Retains Frontier Merchant Capital For North America Investor Relations And Marketing

  8/15/2017

• Sernova Corp.-HemAcure Consortium Announce Significant Progress In Development Of ‘First In World’ Regenerative Medicine Therapy For Treatment Of Hemophilia A Patients

  7/24/2017

• Sernova Corp. And CTI - Clinical Trial and Consulting Services Announce Regulatory Collaboration

  11/2/2016

• Sernova Corp. Honoured As Member Of The "2016 TSX Venture 50" And Ranked #4 In Life Sciences And Clean Technologies

  2/5/2016

• Sernova Corp. Announces Annual Meeting, Record Date And Adopts Advance Notice By-Law

  2/26/2014

• Sernova Corp. Announces Appointment Of Cathy Steiner As CFO

  1/31/2014

• Sernova Corp. to Present at the OneMedForum San Francisco 2011 Conference

  1/12/2011

• Sernova Corp. Expands Scientific Advisory Board

  10/19/2010

• Pioneer in Islet Transplantation, Dr. James Shapiro, Joins Sernova Corp. Scientific Advisory Board

  9/21/2010